We called Oklo a buy and NuScale a strong buy when nuclear fever gripped the market, and the trade collapsed spectacularly. Here is what the bull case looks like after the wreckage, and whether anything has actually changed.
NuScale Power (NYSE:SMR) stock trades at $7.18, down 49% year to date, which puts it deep in the red alongside other reactor developers.
SMR's ENTRA1 partnership could unlock TVA deployment, data-center demand and industrial uses as commercial talks advance.
NuScale Power's regulatory head start, deployment readiness and commercial ambitions offer investors plenty to weigh as the nuclear developer approaches a pivotal phase.
NuScale will reclaim its 52-week high with commercial progress. The company could deploy 72 modules for the biggest SMR project in U.S. history.
The transaction realized a total value of ~$190,000 at a weighted average price of $9.49 per share. The transaction size represents 21% of the direct equity stake held before the filing.
NuScale Power sees hydrogen as a promising growth avenue, with its modular reactors able to supply carbon-free hydrogen, power and heat near industrial users.
NuScale Power stock has dropped 40% in 2026. One Wall Street expert still rates the stock a buy.
SMR advances SMR commercialization as NuScale and MillenniTEK fabricate boron-oxide pellets for its passive emergency core cooling system.
X-Energy is rated a Buy based on its strong management, technology moat, and de-risked commercialization path. XE's Xe-100 reactor leverages TRISO fuel for superior safety, passive shutdown, and rapid construction, reducing capital costs and build times. The company's vertical integration, notably its TRISO-X facility, addresses critical fuel supply bottlenecks and enhances commercialization prospects.
SMR is pairing nuclear expertise with purpose-built AI to speed information retrieval and support advanced reactor deployment.
NuScale Power receives a speculative Buy rating at $9.44, with a five-year horizon focused on commercialization milestones. TVA remains the key growth catalyst; a definitive PPA could transform SMR's revenue trajectory and validate its unique regulatory and supply chain position. Despite a strong $1.9B cash balance, dilution and milestone payments tied to ENTRA1 agreements temper the near-term investment case.